Jazz Pharmaceuticals plc APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Jazz Pharmaceuticals plc (JAZZ) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $74.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $74.90M, a 11.96% increase year-over-year.
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $73.70M, a 9.51% increase year-over-year.
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $88.47M, a 47.03% increase year-over-year.
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $66.90M, a 17.91% increase year-over-year.
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $294.29M, a 17.39% increase from fiscal 2024.
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $250.69M, a 10.28% increase from fiscal 2023.
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $227.32M, a 1.81% increase from fiscal 2022.
- Jazz Pharmaceuticals plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $223.28M, a 17.86% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $74.90M 10-Q · filed 2026-08-03 | $148.60M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $73.70M 10-Q · filed 2026-08-03 | ||||
| 2025-12-31 | $294.29M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $88.47M 10-Q · filed 2025-11-05 | $155.37M derived: sum of 2 quarters · filed 2026-08-03 | $222.67M derived: sum of 3 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $66.90M 10-Q · filed 2026-08-03 | $66.87M 10-Q · filed 2025-08-06 | $134.20M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $67.30M 10-Q · filed 2026-08-03 | $67.33M 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $250.69M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $60.17M 10-Q · filed 2025-11-05 | $116.91M derived: sum of 2 quarters · filed 2025-11-05 | $180.04M derived: sum of 3 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $56.74M 10-Q · filed 2025-11-05 | $119.87M derived: sum of 2 quarters · filed 2025-11-05 | |||
| 2024-03-31 | $63.13M 10-Q · filed 2025-11-05 | ||||
| 2023-12-31 | $227.32M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $56.20M 10-Q · filed 2024-11-07 | $117.90M derived: sum of 2 quarters · filed 2024-11-07 | $174.55M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $61.70M 10-Q · filed 2024-11-07 | $118.35M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $56.65M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $223.28M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $56.98M 10-Q · filed 2023-11-08 | $111.39M derived: sum of 2 quarters · filed 2023-11-08 | $161.50M derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $54.41M 10-Q · filed 2023-11-08 | $104.51M derived: sum of 2 quarters · filed 2023-11-08 | |||
| 2022-03-31 | $50.11M 10-Q · filed 2023-11-08 | ||||
| 2021-12-31 | $189.45M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $54.01M 10-Q · filed 2022-11-09 | $102.13M derived: sum of 2 quarters · filed 2022-11-09 | $136.69M derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $48.12M 10-Q · filed 2022-11-09 | $82.68M derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $34.56M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $121.09M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $30.31M 10-Q · filed 2021-11-09 | $60.91M derived: sum of 2 quarters · filed 2021-11-09 | $89.64M derived: sum of 3 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $30.60M 10-Q · filed 2021-11-09 | $59.33M derived: sum of 2 quarters · filed 2021-11-09 | |||
| 2020-03-31 | $28.73M 10-Q · filed 2021-11-09 | ||||
| 2019-12-31 | $111.30M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $28.82M 10-Q · filed 2020-11-02 | $57.48M derived: sum of 2 quarters · filed 2020-11-02 | $85.34M derived: sum of 3 quarters · filed 2020-11-02 | $112.39M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-06-30 | $28.66M 10-Q · filed 2020-11-02 | $56.52M derived: sum of 2 quarters · filed 2020-11-02 | $83.57M derived: sum of 3 quarters · filed 2021-02-23 | $108.68M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-03-31 | $27.86M 10-Q · filed 2020-11-02 | $54.91M derived: sum of 2 quarters · filed 2021-02-23 | $80.02M derived: sum of 3 quarters · filed 2021-02-23 | $106.32M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2018-12-31 | $27.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $52.16M derived: sum of 2 quarters · filed 2021-02-23 | $78.46M derived: sum of 3 quarters · filed 2021-02-23 | $102.73M 10-K · filed 2021-02-23 | |
| 2018-09-30 | $25.11M 10-Q · filed 2019-11-05 | $51.41M derived: sum of 2 quarters · filed 2019-11-05 | $75.68M 10-Q · filed 2018-11-06 | $103.19M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | $26.29M 10-Q · filed 2019-11-05 | $50.57M 10-Q · filed 2018-08-07 | $78.08M derived: sum of 3 quarters · filed 2020-02-25 | $105.22M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-03-31 | $24.28M 10-Q · filed 2019-11-05 | $51.78M derived: sum of 2 quarters · filed 2020-02-25 | $78.93M derived: sum of 3 quarters · filed 2020-02-25 | $106.23M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2017-12-31 | $27.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $54.65M derived: sum of 2 quarters · filed 2020-02-25 | $81.95M derived: sum of 3 quarters · filed 2020-02-25 | $107.25M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $27.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $54.45M derived: sum of 2 quarters · filed 2018-11-06 | $79.75M 10-Q · filed 2018-11-06 | $103.96M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | $27.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $52.60M 10-Q · filed 2018-08-07 | $76.82M derived: sum of 3 quarters · filed 2019-02-26 | $101.66M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | $25.30M 10-Q · filed 2018-05-08 | $49.51M derived: sum of 2 quarters · filed 2019-02-26 | $74.36M derived: sum of 3 quarters · filed 2019-02-26 | $100.08M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | $24.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $49.06M derived: sum of 2 quarters · filed 2019-02-26 | $74.78M derived: sum of 3 quarters · filed 2019-02-26 | $99.39M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $24.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $50.57M derived: sum of 2 quarters · filed 2017-11-07 | $75.18M 10-Q · filed 2017-11-07 | $99.24M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $25.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $50.33M 10-Q · filed 2017-08-08 | $74.40M derived: sum of 3 quarters · filed 2018-02-27 | $97.73M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $24.61M 10-Q · filed 2017-05-09 | $48.67M derived: sum of 2 quarters · filed 2018-02-27 | $72.01M derived: sum of 3 quarters · filed 2018-02-27 | $95.51M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | $24.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $47.40M derived: sum of 2 quarters · filed 2018-02-27 | $70.90M derived: sum of 3 quarters · filed 2018-02-27 | $91.80M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $23.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $46.83M derived: sum of 2 quarters · filed 2016-11-08 | $67.73M 10-Q · filed 2016-11-08 | $86.87M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | $23.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $44.39M 10-Q · filed 2016-08-09 | $63.53M derived: sum of 3 quarters · filed 2017-02-28 | $81.97M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | $20.90M 10-Q · filed 2016-05-10 | $40.03M derived: sum of 2 quarters · filed 2017-02-28 | $58.48M derived: sum of 3 quarters · filed 2017-02-28 | $76.64M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2014-12-31 | $19.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $37.58M derived: sum of 2 quarters · filed 2017-02-28 | $55.74M derived: sum of 3 quarters · filed 2017-02-28 | $70.06M 10-K · filed 2017-02-28 | |
| 2014-09-30 | $18.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $36.61M derived: sum of 2 quarters · filed 2015-11-09 | $50.92M 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | $18.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $32.48M 10-Q · filed 2015-08-05 | |||
| 2014-03-31 | $14.31M 10-Q · filed 2015-05-07 | ||||
| 2013-12-31 | $44.37M 10-K · filed 2016-02-23 | ||||
| 2012-12-31 | $23.13M 10-K · filed 2015-02-24 | ||||
| 2011-12-31 | $20.50M 10-K · filed 2014-02-25 | ||||
| 2010-12-31 | $8.00M 10-K · filed 2013-02-26 | ||||
| 2009-12-31 | $5.73M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |